Publications by authors named "Jean-Baptiste Briere"

Claim this Profile
G
Generalized anxiety disorder: epidemiology, burden, and comorbid depression.
Annie Druet-Cabanac, Jessica Azzi, Marco Lucchino, Virginie Simon, Lucile Offredo, Jean-Baptiste Briere

Curr Med Res Opin· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients.
Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf

Int Clin Psychopharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective.
Pierre Levy, Tobiasz Lemański, Catriona Crossan, Anna Lefebvre, Jean-Baptiste Brière

Expert Rev Pharmacoecon Outcomes Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis.
André Pascal Kengne, Jean-Baptiste Brière, Pauline Le Nouveau, Petya Kodjamanova, Petar Atanasov

Expert Rev Pharmacoecon Outcomes Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review.
André Pascal Kengne, Jean-Baptiste Brière, Irene Asensio Gudiña, Xiaobin Jiang, Petya Kodjamanova

Expert Rev Pharmacoecon Outcomes Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review.
André Pascal Kengne, Jean-Baptiste Brière, Lucía Zhu, Jingya Li, Mandeep Kaur Bhatia

Expert Rev Pharmacoecon Outcomes Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivabradine in patients with heart failure: a systematic literature review.
Zeba M Khan, Jean Baptiste Briere, Elzbieta Olewinska, Fatma Khrouf, Mateusz Nikodem

J Mark Access Health Policy· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England.
Laura Portas, Rupert Bauersachs, Kevin Bowrin, Jean-Baptiste Briere, Alexander Cohen

Vasc Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Jean-Baptiste Briere

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease.
Marc Schindewolf, Jan Beyer-Westendorf, Janita Balradj, Kevin Bowrin, Maria Huelsebeck, Jean-Baptiste Briere

Angiology· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of real-world evidence in meta-analyses and cost-effectiveness models.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Mondher Toumi, Aurélie Millier

J Med Econ· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Martin R Cowie, André Lamy, Pierre Levy, Stuart Mealing, Aurélie Millier, Jean-Baptiste Briere

Cardiovasc Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Rupert Bauersachs, Olivia Wu, Jean-Baptiste Briere, Kevin Bowrin, Katarzyna Borkowska

Cardiovasc Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Erkki Soini, Outi Virtanen, Saku Väätäinen, Jean-Baptiste Briere, Kevin Bowrin

Adv Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Jean Tardu

J Mark Access Health Policy· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015.
Varun Sundaram, Chloe Bloom, Rosita Zakeri, Julian Halcox, Alexander Cohen, Jean-Baptiste Briere

Eur Heart J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.
Corinne Emery, Elodie Torreton, Jean-Baptiste Briere, Thomas Evers, Francis Fagnani

J Med Econ· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review.
Rupert Bauersachs, Uwe Zeymer, Jean-Baptiste Brière, Caroline Marre, Kevin Bowrin

Cardiovasc Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease.
Rupert Bauersachs, Sebastian Debus, Mark Nehler, Maria Huelsebeck, Janita Balradj, Jean-Baptiste Briere

Angiology· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Jean-Baptiste Briere, Olivia Wu, Kevin Bowrin, Aurélie Millier, Mondher Toumi

Curr Med Res Opin· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France.
Paul Guedeney, Victor Aboyans, Faustine Dalon, Dina Oksen, Manon Belhassen, Jean-Baptiste Briere

Arch Cardiovasc Dis· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Jean-Baptiste Briere, Kevin Bowrin, Aurélie Millier, Mondher Toumi, Piotr Wojciechowski

J Med Econ· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation.
Emi Watanabe-Fujinuma, Benjamin F Banderas, Yukihiro Koretsune, Koichiro Kumagai, Shinichiro Uchiyama, Jean-Baptiste Briere

J Med Econ· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analyses using real-world data: an overview of the literature.
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Emilie Clay

J Med Econ· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis